Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

62.10 -0.53 (-0.84%)
Streaming Delayed Price Updated: 3:38 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,625,077
Open 60.67
Bid (Size) 62.10 (3)
Ask (Size) 62.11 (3)
Prev. Close 62.63
Today's Range 60.57 - 62.27
52wk Range 57.00 - 148.15
Shares Outstanding N/A
Dividend Yield 3.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy
The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's decision on semaglutide shortage. 
Via Benzinga
Exposures Product Safety
Novo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s Bullish
Steve Benz, legal and US general counsel of Novo Nordisk, said the company is “pleased” that the court rejected the compounders' attempts to “undermine” the FDA's decision that the shortages of Wegovy... 
Via Stocktwits
Topics Lawsuit
Exposures Financial Legal Product Safety

Performance

YTD
-29.04%
-29.04%
1 Month
-15.62%
-15.62%
3 Month
-23.42%
-23.42%
6 Month
-45.48%
-45.48%
1 Year
-50.77%
-50.77%

More News

Read More
Why Novo Nordisk Stock Dropped Today
Via The Motley Fool
Top 2 Health Care Stocks That May Crash This Month
Via Benzinga
The Best Stock to Buy With Less Than $60 in the Market Sell-Off
Via The Motley Fool
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
Via Benzinga
Topics Government
Exposures Political
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Via MarketBeat
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Via Benzinga
Why Novo Nordisk Stock Popped Today
Via The Motley Fool
Exposures Product Safety
Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop
Via Investor's Business Daily
Exposures Product Safety
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Via The Motley Fool
Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry
Via Stocktwits
Exposures Product Safety
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Via The Motley Fool
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Government
Exposures Political
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Via Benzinga
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Via Benzinga
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.